NewsGlobeNewswire
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
· Published
Article summary
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…